Cancer patients have the highest probability of
recovering if tumors are completely removed. However, tiny clusters of cancer
cells are often difficult for surgeons to recognize and remove. A camera makes
hidden tumors visible during an operation.
Tumor removal surgeries pose a great challenge
even to skillful and experienced surgeons. For one thing, tumor margins are
blending into healthy tissue and are difficult to differentiate. For another,
distributed domains of cancer and pre-malignancies are difficult to recognize.
Up to now, doctors depend exclusively upon their trained eyes when excising
pieces of tumors. In future, a new special camera system can help visualize
during operation even the smallest, easy-to-overlook malignant pieces of tumor
and thereby support the surgeons during complicated interventions.
The trick: the camera can display fluorescent
molecules that “paint” the cancer tissue. These are injected into the patient’s
blood circulation prior to the operation and selectively attach onto the tumor
during their trip through the body. If the corresponding area is then illuminated
with a specific wavelength, fluorescence is emitted and the malignant tissue
glows green, blue, red, or any other color, depending on the injected dye,
while the healthy tissue appears the same. In this way, the surgeon can see
clusters of tumors cells that cannot be recognized by the naked eye.New system reveals
several dyes simultaneously.
Researchers at the Fraunhofer Project Group for
Automation in Medicine and Biotechnology (PAMB), which belongs to the
Fraunhofer Institute for Manufacturing Engineering and Auto- mation (IPA), have
developed a new surgical aid, a multispectral fluorescence camera system. In
the future, this special camera will integrate into various medical imaging
systems such as, surgical microscopes and endoscopes, etc. The scientists from
Mannheim, Germany, will make the debute of a prototype of this high-tech system
at the Medica Trade Fair in Düsseldorf in the joint Fraunhofer booth (Halle 10,
Booth F05) between 20-23 November. The novel aspect about this camera: it can
display several fluorescent dyes and the reflectance image simultaneously in
real time – systems available until now have not been able to achieve this. The
advantage: arteries and delicate nerves that must not be injured during an
intervention can likewise be colored with dye. They too can then be detected
with the new camera, since they are set apart from their surroundings.
“The visibility of the dye to the camera depends
in large part on the selection of the correct set of fluorescence filters. The
filter separates the incident excitation wave- lengths from the fluorescing
wavelengths so that the diseased tissue is also set apart from its surround-
ings, even at very low light intensities,” says Nikolas Dimitriadis, a
scientist at PAMB. The researchers and their colleague require only one camera
and one set of filters for their photographs, which can present up to four dyes
at the same time. Software developed in-house analyses and processes the images
in seconds and presents it continuously on a monitor during surgery. The
information from the fluores- cent image is superposed on the normal color
image. “The operator receives significantly more accurate information.
Millimeter-sized tumor remnants or metastases that a surgeon would otherwise
possibly overlook are recognizable in detail on the monitor. Patients operated
under fluorescent light have improved chances of survival,” says Dr. Nikolas
Dimitriadis, head of the Biomedical Optics Group at PAMB.
In order to be able to employ the multispectral
fluorescence camera system as adapt- ably as possible, it can be converted to
other combinations of dyes. “One preparation that is already available to make
tumors visible is 5-amino levulinic acid (5-ALA). Physicians employ this
especially for glioblastomas – one of the most frequent malignant brain tumors
in adults,” explains Dimitriadis. 5-ALA leads to an accumulation of a red dye
in the tumor and can likewise be detected with the camera. The multispectral
fluorescence imaging system should have passed testing for use with humans as
soon as next year. The first clinical tests with patients suffering from
glioblastomas are planned for 2014.
Posted by
Gauri Shah (faculty)
Bioinformatics Institute of India
No comments:
Post a Comment